Aquestive Therapeutics, Inc. Income Statement
AQST|8 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
Aquestive Therapeutics, Inc. reported $45M in revenue and $84M in net loss for FY2025. Revenue has declined at a 5.6% compound annual rate over the past 7 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $44.5M | $57.6M | $50.6M | $47.7M | $45.8M | $52.6M | $67.4M | $66.9M |
| Cost of Revenue | $18.6M | $17.9M | $20.8M | $19.4M | - | $20.4M | - | - |
| SG&A Expense | $79.8M | $50.2M | $31.8M | $52.9M | $55.9M | $64.3M | $72.3M | $25.1M |
| R&D Expense | $17.2M | $20.3M | $13.1M | $17.5M | $19.9M | $20.6M | $23.1M | $22.1M |
| Operating Income | -$71.1M | -$30.8M | -$15.1M | -$42.1M | -$42.9M | -$52.7M | -$48.9M | -$113.0K |
| Interest Expense | - | - | $6.3M | $6.6M | $11.1M | $9.3M | $7.7M | $7.7M |
| Income Tax | $0 | -$14.0K | $245.0K | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$83.8M | -$44.1M | -$7.9M | -$54.4M | -$55.8M | -$66.2M | -$61.4M | -$8.9M |
| EPS (Basic) | -$0.51 | -$0.13 | -$1.12 | -$1.85 | -$1.66 | - | - | - |
| EPS (Diluted) | -$0.51 | -$0.13 | -$1.12 | -$1.85 | -$1.66 | -$2.61 | -$2.96 | $0.27 |
| Shares Outstanding | 91.4M | 68.5M | 54.8M | 41.2M | 34.6M | 33.6M | 25.0M | 25.0M |
| Operating Margin | -159.5% | -53.5% | -29.9% | -88.2% | -93.5% | -100.1% | -72.6% | -0.2% |
| Profit Margin | -188.1% | -76.7% | -15.6% | -114.1% | -121.7% | -125.9% | -91.0% | -13.4% |